These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 27611691)

  • 1. Preclinical Metabolism, Pharmacokinetics and In Vivo Analysis of New Blood-Brain-Barrier Penetrant Fingolimod Analogues: FTY720-C2 and FTY720-Mitoxy.
    Enoru JO; Yang B; Krishnamachari S; Villanueva E; DeMaio W; Watanyar A; Chinnasamy R; Arterburn JB; Perez RG
    PLoS One; 2016; 11(9):e0162162. PubMed ID: 27611691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720-Mitoxy reduces synucleinopathy and neuroinflammation, restores behavior and mitochondria function, and increases GDNF expression in Multiple System Atrophy mouse models.
    Vidal-Martinez G; Segura-Ulate I; Yang B; Diaz-Pacheco V; Barragan JA; De-Leon Esquivel J; Chaparro SA; Vargas-Medrano J; Perez RG
    Exp Neurol; 2020 Mar; 325():113120. PubMed ID: 31751571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FTY720-Mitoxy reduces toxicity associated with MSA-like α-synuclein and oxidative stress by increasing trophic factor expression and myelin protein in OLN-93 oligodendroglia cell cultures.
    Vargas-Medrano J; Segura-Ulate I; Yang B; Chinnasamy R; Arterburn JB; Perez RG
    Neuropharmacology; 2019 Nov; 158():107701. PubMed ID: 31291595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pilot Microbiota Study in Parkinson's Disease Patients versus Control Subjects, and Effects of FTY720 and FTY720-Mitoxy Therapies in Parkinsonian and Multiple System Atrophy Mouse Models.
    Vidal-Martinez G; Chin B; Camarillo C; Herrera GV; Yang B; Sarosiek I; Perez RG
    J Parkinsons Dis; 2020; 10(1):185-192. PubMed ID: 31561385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Up-regulation of protective neuronal MicroRNAs by FTY720 and novel FTY720-derivatives.
    Vargas-Medrano J; Yang B; Garza NT; Segura-Ulate I; Perez RG
    Neurosci Lett; 2019 Jan; 690():178-180. PubMed ID: 30359694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel FTY720-Based Compounds Stimulate Neurotrophin Expression and Phosphatase Activity in Dopaminergic Cells.
    Vargas-Medrano J; Krishnamachari S; Villanueva E; Godfrey WH; Lou H; Chinnasamy R; Arterburn JB; Perez RG
    ACS Med Chem Lett; 2014 Jul; 5(7):782-6. PubMed ID: 25050165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chitosan nanocarrier for FTY720 enhanced delivery retards Parkinson's disease via PP2A-EzH2 signaling in vitro and ex vivo.
    Sardoiwala MN; Karmakar S; Choudhury SR
    Carbohydr Polym; 2021 Feb; 254():117435. PubMed ID: 33357908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720-derivatives do not induce FTY720-like lymphopenia.
    Segura-Ulate I; Belcher TK; Vidal-Martinez G; Vargas-Medrano J; Perez RG
    J Pharmacol Sci; 2017 Mar; 133(3):187-189. PubMed ID: 28363412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod targeting protein phosphatase 2A differently affects IL-33 induced IL-2 and IFN-γ production in CD8(+) lymphocytes.
    Ottenlinger F; Schwiebs A; Pfarr K; Wagner A; Grüner S; Mayer CA; Pfeilschifter JM; Radeke HH
    Eur J Immunol; 2016 Apr; 46(4):941-51. PubMed ID: 26683421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential anti-tumor effects of FTY720 associated with PP2A activation: a brief review.
    Cristóbal I; Madoz-Gúrpide J; Manso R; González-Alonso P; Rojo F; García-Foncillas J
    Curr Med Res Opin; 2016 Jun; 32(6):1137-41. PubMed ID: 26950691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice: CONTRIBUTIONS OF PRO-BRAIN-DERIVED NEUROTROPHIC FACTOR (PRO-BDNF) AND MATURE BDNF.
    Vidal-Martínez G; Vargas-Medrano J; Gil-Tommee C; Medina D; Garza NT; Yang B; Segura-Ulate I; Dominguez SJ; Perez RG
    J Biol Chem; 2016 Sep; 291(39):20811-21. PubMed ID: 27528608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulator-Derived Nanoparticles Induce Neuroprotection and Regulatory T Cell Action to Alleviate Parkinsonism.
    Sardoiwala MN; Biswal L; Choudhury SR
    ACS Appl Mater Interfaces; 2024 Jul; 16(30):38880-38892. PubMed ID: 39016239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.
    Szymiczek A; Pastorino S; Larson D; Tanji M; Pellegrini L; Xue J; Li S; Giorgi C; Pinton P; Takinishi Y; Pass HI; Furuya H; Gaudino G; Napolitano A; Carbone M; Yang H
    J Transl Med; 2017 Mar; 15(1):58. PubMed ID: 28298211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FTY720 attenuates excitotoxicity and neuroinflammation.
    Cipriani R; Chara JC; Rodríguez-Antigüedad A; Matute C
    J Neuroinflammation; 2015 May; 12():86. PubMed ID: 25953296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NMR-based characterization of the FTY720-SET complex reveals an alternative mechanism for the attenuation of the inhibitory SET-PP2A interaction.
    De Palma RM; Parnham SR; Li Y; Oaks JJ; Peterson YK; Szulc ZM; Roth BM; Xing Y; Ogretmen B
    FASEB J; 2019 Jun; 33(6):7647-7666. PubMed ID: 30917007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury.
    Cipriani R; Chara JC; Rodríguez-Antigüedad A; Matute C
    J Neuroinflammation; 2017 Jul; 14(1):147. PubMed ID: 28738875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod (FTY720-P) Does Not Stabilize the Blood-Brain Barrier under Inflammatory Conditions in an in Vitro Model.
    Schuhmann MK; Bittner S; Meuth SG; Kleinschnitz C; Fluri F
    Int J Mol Sci; 2015 Dec; 16(12):29454-66. PubMed ID: 26690412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.
    Vidal-Martinez G; Najera K; Miranda JD; Gil-Tommee C; Yang B; Vargas-Medrano J; Diaz-Pacheco V; Perez RG
    Neuroscience; 2019 Jul; 411():1-10. PubMed ID: 31129200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.